Upon administering this first dose in Boca Raton, GenesisCare plans to continue to add the agent to a number of centers across the U.S.
"Nuclear medicine, including PYLARIFY PET imaging, is now a pivotal medical specialty that can transform patients by optimizing treatment selection," said Dr. Neal D. Shore, U.S. Chief Medical Officer of Surgery and Urology, GenesisCare. "The approval by the FDA for public use of this PET PSMA imaging agent provides critical accessibility which will improve prostate cancer patient management nationwide."
Ad Statistics
Times Displayed: 31443
Times Visited: 833 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
As a leading provider of oncology services globally, GenesisCare strives to ensure the best possible life outcomes for its patients by bringing integrated cancer care, research, and medical technology together for each individual. With its origins in radiation oncology, GenesisCare has, in recent years, expanded its services to include medical oncology, urology and surgery, and nuclear medicine, a rapidly developing field of oncology care.
About GenesisCare
GenesisCare is a Sydney and Australian Headquartered private company and is one of the world's largest cancer treatment providers. The organization has committed more than $U.S.300 million to upgrade technology and cancer treatment services across the United States. Every year GenesisCare clinical teams see more than 400,000 people at more than 440 locations. This includes our 293 locations in the U.S., 38 locations in Australia, 14 in the U.K., and 21 in Spain. Globally, the organization employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, the UK, Spain, and now in the U.S.
GenesisCare is heavily focused on clinical research and innovation in healthcare and leads or is a part of more than 150 clinical trials worldwide.
Our purpose is to design care experiences that get the best possible life outcomes. We believe that care should be focused on the individual, not the condition, and are proud of our world-class patient satisfaction ratings.
About PYLARIFY
PYLARIFY® (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. The recommended PYLARIFY dose is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi), administered as a bolus intravenous injection.
SOURCE GenesisCare
Back to HCB News
